Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

RheumaGen raises $15M Series A for HLA gene editing in autoimmune diseases, while RyboDyn gets $4M pre-seed to study non-coding DNA for cancer immunotherapies ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.